• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $STAA

    STAAR Surgical Company

    Subscribe to $STAA
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

    IPO Year:

    Exchange: NASDAQ

    Website: staar.com

    Recent Analyst Ratings for STAAR Surgical Company

    DatePrice TargetRatingAnalyst
    4/21/2025$17.00Equal Weight
    Wells Fargo
    2/12/2025Buy → Hold
    Jefferies
    2/12/2025$45.00 → $17.00Outperform → Neutral
    Mizuho
    2/12/2025Buy → Neutral
    BTIG Research
    2/12/2025Outperform → Mkt Perform
    William Blair
    7/15/2024$50.00 → $37.00Equal-Weight → Underweight
    Morgan Stanley
    6/11/2024$46.00Neutral → Buy
    BTIG Research
    3/11/2024$30.00 → $50.00Hold → Buy
    Stifel
    12/5/2023Buy → Hold
    Needham
    12/4/2023$35.00Equal-Weight
    Morgan Stanley
    See more ratings

    STAAR Surgical Company Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on STAAR Surgical with a new price target

    Wells Fargo initiated coverage of STAAR Surgical with a rating of Equal Weight and set a new price target of $17.00

    4/21/25 8:38:55 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical downgraded by Jefferies

    Jefferies downgraded STAAR Surgical from Buy to Hold

    2/12/25 11:13:24 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical downgraded by Mizuho with a new price target

    Mizuho downgraded STAAR Surgical from Outperform to Neutral and set a new price target of $17.00 from $45.00 previously

    2/12/25 7:11:03 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical downgraded by BTIG Research

    BTIG Research downgraded STAAR Surgical from Buy to Neutral

    2/12/25 7:11:03 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical downgraded by William Blair

    William Blair downgraded STAAR Surgical from Outperform to Mkt Perform

    2/12/25 7:11:03 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded STAAR Surgical from Equal-Weight to Underweight and set a new price target of $37.00 from $50.00 previously

    7/15/24 7:50:20 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical upgraded by BTIG Research with a new price target

    BTIG Research upgraded STAAR Surgical from Neutral to Buy and set a new price target of $46.00

    6/11/24 7:19:51 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical upgraded by Stifel with a new price target

    Stifel upgraded STAAR Surgical from Hold to Buy and set a new price target of $50.00 from $30.00 previously

    3/11/24 7:47:40 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical downgraded by Needham

    Needham downgraded STAAR Surgical from Buy to Hold

    12/5/23 7:38:00 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Morgan Stanley initiated coverage on STAAR Surgical with a new price target

    Morgan Stanley initiated coverage of STAAR Surgical with a rating of Equal-Weight and set a new price target of $35.00

    12/4/23 7:59:23 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Company Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Broadwood Partners, L.P. bought $2,866,428 worth of shares (187,227 units at $15.31) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    4/10/25 7:00:22 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Large owner Broadwood Partners, L.P. bought $13,627,504 worth of shares (845,220 units at $16.12) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    4/7/25 8:28:12 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Large owner Broadwood Partners, L.P. bought $941,285 worth of shares (53,969 units at $17.44) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    4/2/25 8:33:34 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Large owner Broadwood Partners, L.P. bought $1,983,824 worth of shares (113,384 units at $17.50) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    3/28/25 6:45:56 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Large owner Broadwood Partners, L.P. bought $2,414,722 worth of shares (136,696 units at $17.66) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    3/25/25 7:02:36 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Large owner Broadwood Partners, L.P. bought $3,586,283 worth of shares (201,844 units at $17.77) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    3/20/25 7:51:11 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Large owner Broadwood Partners, L.P. bought $481,849 worth of shares (27,953 units at $17.24) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    3/6/25 7:07:57 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Large owner Broadwood Partners, L.P. bought $11,275,555 worth of shares (663,761 units at $16.99) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    3/3/25 7:12:54 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Large owner Broadwood Partners, L.P. bought $6,274,767 worth of shares (411,430 units at $15.25) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    2/14/25 7:00:26 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Large owner Broadwood Partners, L.P. bought $630,839 worth of shares (29,376 units at $21.47) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    1/16/25 7:20:21 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Company Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jiang Wei converted options into 20,967 shares, increasing direct ownership by 592% to 24,510 units (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    8/13/25 6:39:57 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form 4 filed by CFO Andrews Deborah J

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    6/26/25 6:31:03 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form 4 filed by Director Zhou Lilian Yansheng

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    6/26/25 6:29:04 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form 4 filed by Director Silverman Lou

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    6/20/25 5:23:05 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form 4 filed by Director Jiang Wei

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    6/20/25 5:22:08 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form 4 filed by Director Zhou Lilian Yansheng

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    6/20/25 5:21:27 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form 4 filed by Director Butcher Arthur C

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    6/20/25 5:20:51 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form 4 filed by Director Lin Elizabeth Yeu

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    6/20/25 5:20:04 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Chief Development Officer Michna Magda covered exercise/tax liability with 1,675 shares, decreasing direct ownership by 10% to 14,444 units (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    5/14/25 8:41:13 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form 4 filed by Director Silverman Lou

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    5/13/25 6:04:36 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Company SEC Filings

    View All

    SEC Form DEFA14A filed by STAAR Surgical Company

    DEFA14A - STAAR SURGICAL CO (0000718937) (Filer)

    9/30/25 8:48:23 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form DEFA14A filed by STAAR Surgical Company

    DEFA14A - STAAR SURGICAL CO (0000718937) (Filer)

    9/26/25 11:52:17 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Company filed SEC Form 8-K: Regulation FD Disclosure

    8-K - STAAR SURGICAL CO (0000718937) (Filer)

    9/26/25 9:14:06 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form DEFA14A filed by STAAR Surgical Company

    DEFA14A - STAAR SURGICAL CO (0000718937) (Filer)

    9/22/25 7:42:04 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form DEFA14A filed by STAAR Surgical Company

    DEFA14A - STAAR SURGICAL CO (0000718937) (Filer)

    9/19/25 4:05:58 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form DEFA14A filed by STAAR Surgical Company

    DEFA14A - STAAR SURGICAL CO (0000718937) (Filer)

    9/16/25 9:16:41 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form DEFA14A filed by STAAR Surgical Company

    DEFA14A - STAAR SURGICAL CO (0000718937) (Filer)

    9/16/25 8:55:16 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form DEFM14A filed by STAAR Surgical Company

    DEFM14A - STAAR SURGICAL CO (0000718937) (Filer)

    9/16/25 8:51:09 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form DEFA14A filed by STAAR Surgical Company

    DEFA14A - STAAR SURGICAL CO (0000718937) (Filer)

    9/5/25 4:07:23 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form DEFA14A filed by STAAR Surgical Company

    DEFA14A - STAAR SURGICAL CO (0000718937) (Filer)

    9/2/25 5:22:49 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Company Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alcon and STAAR Surgical Announce Expiration of Hart-Scott-Rodino Waiting Period for Alcon's Acquisition of STAAR

    Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ:STAA) ("STAAR"), the manufacturer of the Implantable Collamer® Lens (ICL), today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), in connection with Alcon's acquisition of STAAR, expired at 11:59 p.m. ET on September 29, 2025. As previously announced, under the terms of the agreement, Alcon will purchase all outstanding shares of STAAR common stock for $28 per share in cash, which represents approximately a 59% premium to STAAR's 90-day volume weighted average price and a 51% premium to the cl

    9/30/25 8:30:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Publishes Presentation Highlighting Compelling, Certain Cash Value Offered by Alcon Merger and Meaningful Downside Risks if Alcon Merger is not Approved

    Proposed Merger Represents a Compelling 59% Premium to the 90-Day VWAP Prior to Announcement STAAR's Business Risks and Challenges are Increasing and Competition is Intensifying China Net Sales, which Represent Approximately Half of STAAR's Consolidated Net Sales, Have Declined Since 2023, and Procedure Volumes Remain Weak Broadwood Partners' Claims Against the Merger are Flawed and Misleading and Reflect a Misunderstanding of STAAR's Standalone Challenges, Value, and Potential Buyer Interest in STAAR STAAR's Stock Traded at $18.49 per Share Prior to Announcement – If the Merger is not Approved, STAAR Expects its Valuation Would Face Considerable Downward Pressure, Especially in Lig

    9/26/25 8:00:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    Broadwood Partners Files Definitive Proxy Statement Soliciting STAAR Surgical Stockholders to Vote "AGAINST" Proposed Acquisition by Alcon

    Outlines Its Belief that the Proposed Transaction Is the Product of Bad Timing, a Flawed Process, and Significant Conflicts of Interest Broadwood Believes the Transaction Delivers Less Value than Alternatives, Including a Properly Run Strategic Alternatives Process or Improved Execution as a Standalone Business Sends Letter to STAAR Stockholders Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood"), holders of approximately 27.5% of the outstanding common stock of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) today announced that it has filed a definitive proxy statement and GREEN proxy card with the U.S. Securities and Exchange Commission (the "SEC

    9/24/25 8:00:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Announces Expiration of "Window Shop" Period; No Competing Acquisition Proposals Received

    Reinforces STAAR Board's Determination that Alcon Merger Maximizes Stockholder Value and is Best Path Forward for STAAR Stockholders STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the expiration of the 45-day "window shop" period under the terms of the previously announced merger agreement with affiliates of Alcon (SIX/NYSE:ALC). The "window shop" period expired at 11:59 p.m., Eastern Time, on September 19, 2025, and no competing acquisition proposal was received despite Broadwood Partners' active exploration of alternative buyers over the past 45 days. "The expi

    9/22/25 7:15:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    Yunqi Capital, 5.1% Holder and One of STAAR Surgical Company's Largest Shareholders, Announces Intention to Vote Against the Proposed Sale to Alcon

    Issues Open Letter to Shareholders Outlining Its Belief that the Proposed Merger Materially Undervalues STAAR Contends that STAAR's Board Failed In Its Responsibilities by Not Running a Thorough Process and Relying on Undue Skepticism about the Company's Prospects Shareholders Deserve Fair Value for the Company Yunqi Capital Limited (together with its affiliates and the funds it advises, "Yunqi Capital"), an investment management firm and 5.1% shareholder of STAAR Surgical Company ("STAAR") (NASDAQ:STAA), today announced its opposition to the Company's proposed sale to Alcon Inc. (SIX/NYSE:ALC) on the terms announced on August 5, 2025. Yunqi Capital released the following open lette

    9/22/25 6:00:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Board of Directors Unanimously Believes Alcon Merger Maximizes Value for STAAR Stockholders

    Provides Greater Value than STAAR Could Achieve on a Standalone Basis in the Foreseeable Future and is the Best Path Forward for STAAR Stockholders Files Definitive Proxy Materials and Mails Letter to STAAR Stockholders Encourages Stockholders to Vote "FOR" the Value Maximizing Alcon Merger Today STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission in connection with the Company's pending merger with Alcon (SIX/NYSE:ALC). STAAR will hold a Special Meeting of Stockholders

    9/16/25 9:10:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Reiterates Compelling, Premium Cash Value Provided by Alcon Merger

    STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, issued the following statement: "The merger with Alcon provides STAAR stockholders with compelling, premium cash value, including a 51% premium to the closing price of STAAR common stock on August 4, 2025 (the day prior to the agreement being announced) and a 59% premium to STAAR's 90-day Volume Weighted Average Price (VWAP) as of that date. We believe the $28 per share cash value provided by the Alcon agreement exceeds what STAAR could achieve on a standalone basis in the foreseeable future, particularly given STAAR's lower growth

    9/2/25 5:41:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Reports Second Quarter 2025 Results

    STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the second quarter ended June 27, 2025. Second Quarter 2025 Financial Overview Net sales of $44.3 million down 55% Y/Y due to planned reduction of channel inventory in China Net sales excluding China of $39.0 million up 10% Y/Y Gross margin at 74.0% vs. 79.2% year ago due to the decrease in sales volume, but up from 65.8% in Q1 of this year Net loss of $(16.8) million or $(0.34) per share, down from net income of $7.4 million or $0.15 per share year ago, but up from a net loss of $(54.2) million

    8/6/25 4:01:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Alcon Agrees to Acquire STAAR Surgical

    STAAR Surgical is a leader in refractive surgery using Implantable Collamer Lenses, offering solutions for moderate to high myopes Acquisition of STAAR is complementary to Alcon's laser vision correction business and is expected to be accretive in year two Alcon to purchase all outstanding shares of STAAR for $28 per share in cash, valuing STAAR at approximately $1.5 billion in equity value Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the Implantable Collamer® Lens (ICL), today announced the companies have entered into a d

    8/5/25 1:01:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical to Host Second Quarter 2025 Earnings Conference Call and Webcast on August 6, 2025

    STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the second quarter ended June 27, 2025, on Wednesday, August 6, 2025 after the market close. The Company will also host an earnings call and webcast at 4:30 p.m. ET to discuss its financial results and business progress. Event: STAAR Surgical 2Q 2025 Financial Results Webcast Date: Wednesday, August 6, 2025 Time: 4:30 p.m. ET Location: https://registrations.events/direct/IDX8578398 The live webcast, including an option to pre-register, can be accessed at the preceding link o

    7/31/25 10:03:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Company Leadership Updates

    Live Leadership Updates

    View All

    STAAR Surgical Announces Appointment of Deborah Andrews as Chief Financial Officer, Forms Capital Stewardship Committee of the Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that Deborah Andrews has been appointed Chief Financial Officer, effective June 25, 2025. Ms. Andrews has served as Interim CFO since March 2025, and she previously served as STAAR's CFO from 2007-2013 and 2017-2020. "Deborah has blended seamlessly with the leadership team, and we quickly realized that her deep knowledge of STAAR and her skills, abilities, and approach made her the perfect choice to be STAAR's next CFO," said the Company's CEO and Board member, Stephen Farrell. "In the last few months, Deborah has

    6/25/25 9:28:00 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Announces Leadership Transition

    Stephen C. Farrell appointed CEO to succeed Tom Frinzi Elizabeth Yeu, M.D. elected Board Chair STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced a leadership transition. Stephen C. Farrell, current Lead Independent Director of the STAAR Board of Directors, has been appointed President and CEO, effective February 26, 2025. Tom Frinzi, STAAR's current President and CEO, will remain with the Company in an advisory role through January 2026 to support the leadership transition and build upon STAAR's strong relationships in the ophthalmic community. "We are pleased to

    2/26/25 4:45:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel

    New Appointments Underscore Commitment to Driving Innovation and Industry-Leading Growth STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel. Both will serve on the Company's executive committee and report to Tom Frinzi, STAAR Surgical's President and CEO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240501408389/en/Nancy Sabin, Chief Marketing Officer, STAAR Surgical (Photo:

    5/1/24 7:00:00 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Adds Arthur Butcher and Wei Jiang to Board of Directors

    STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced the appointment of Arthur Butcher, Executive Vice President and Group President, MedSurg and Asia Pacific for Boston Scientific, and Wei Jiang, retired Executive Vice President and President of Bayer Pharmaceuticals Region China & APAC, to its Board of Directors, effective March 12, 2024. "Art Butcher and Wei Jiang are seasoned executives with broad leadership experience built over decades at two of the most highly regarded global companies in the healthcare industry," said Aimee Weisner, Chair

    3/12/24 7:00:00 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Lilian Zhou Appointed to STAAR Surgical Board of Directors

    STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced the appointment of Lilian Zhou to its Board of Directors, effective December 4, 2023. "We welcome Lilian Zhou as a new member to our Board of Directors. Lilian is an accomplished investment portfolio manager who worked at highly regarded Wall Street investment institutions before founding her own firm a decade ago," said Aimee Weisner, Chair of the Nominating and Governance Committee of STAAR Surgical's Board of Directors. "We look forward to Lilian's contributions as a former institutional shar

    12/4/23 4:05:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Company Financials

    Live finance-specific insights

    View All

    STAAR Surgical Reports Second Quarter 2025 Results

    STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the second quarter ended June 27, 2025. Second Quarter 2025 Financial Overview Net sales of $44.3 million down 55% Y/Y due to planned reduction of channel inventory in China Net sales excluding China of $39.0 million up 10% Y/Y Gross margin at 74.0% vs. 79.2% year ago due to the decrease in sales volume, but up from 65.8% in Q1 of this year Net loss of $(16.8) million or $(0.34) per share, down from net income of $7.4 million or $0.15 per share year ago, but up from a net loss of $(54.2) million

    8/6/25 4:01:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Alcon Agrees to Acquire STAAR Surgical

    STAAR Surgical is a leader in refractive surgery using Implantable Collamer Lenses, offering solutions for moderate to high myopes Acquisition of STAAR is complementary to Alcon's laser vision correction business and is expected to be accretive in year two Alcon to purchase all outstanding shares of STAAR for $28 per share in cash, valuing STAAR at approximately $1.5 billion in equity value Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the Implantable Collamer® Lens (ICL), today announced the companies have entered into a d

    8/5/25 1:01:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical to Host Second Quarter 2025 Earnings Conference Call and Webcast on August 6, 2025

    STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the second quarter ended June 27, 2025, on Wednesday, August 6, 2025 after the market close. The Company will also host an earnings call and webcast at 4:30 p.m. ET to discuss its financial results and business progress. Event: STAAR Surgical 2Q 2025 Financial Results Webcast Date: Wednesday, August 6, 2025 Time: 4:30 p.m. ET Location: https://registrations.events/direct/IDX8578398 The live webcast, including an option to pre-register, can be accessed at the preceding link o

    7/31/25 10:03:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Announces $30 Million Share Repurchase Authorization

    STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $30 million of its outstanding common stock. "Our decision to initiate a share repurchase program underscores the Board's and management's confidence in STAAR's future and our ability to return to sustainable, profitable growth," said Stephen C. Farrell, Chief Executive Officer of STAAR Surgical. "With a strong balance sheet, no debt, and clear progress in our cost optimization and strategic priorities, we

    5/16/25 7:00:00 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Reports First Quarter 2025 Results

    China ICL Procedure Trends Improving Tariff Mitigation Activities Implemented Cost Controls and Restructuring Initiated to Reduce SG&A Run Rate Earnings Call and Webcast Today at 5:15 p.m. Eastern STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the first quarter ended March 28, 2025. First Quarter 2025 Financial Overview Net sales of $42.6 million down 45% Y/Y due to planned reduction of channel inventory in China Net Sales Excluding China of $42.2 million up 9% Y/Y reflecting growth in all key markets Gross margin at 65.8% vs. 78.9% year ago due

    5/7/25 4:01:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Announces Changes to Board of Directors

    STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

    4/24/25 5:00:00 PM ET
    $AZN
    $CRVL
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Specialty Insurers
    Finance

    STAAR Surgical to Host First Quarter 2025 Earnings Conference Call and Webcast on May 7, 2025

    STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the first quarter ended March 28, 2025, on Wednesday, May 7, 2025 after the market close. The Company will also host an earnings call and webcast at 5:15 p.m. ET to discuss its financial results and business progress. Event: STAAR Surgical 1Q 2025 Financial Results Webcast Date: Wednesday, May 7, 2025 Time: 5:15 p.m. ET Location: https://event.choruscall.com/mediaframe/webcast.html?webcastid=VN5Skdjp The live webcast, including an option to pre-register, can be accessed at the

    4/23/25 7:00:00 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Reports Fourth Quarter and Fiscal Year 2024 Results

    Net Sales of $313.9 Million and ICL Sales of $312.5 Million for Fiscal 2024 Impacted by Weak China Macroeconomic Conditions ICL Sales Ex. China Up 17% in Fourth Quarter and 13% in Fiscal 2024 Introduces Outlook for Fiscal 2025 Earnings Conference Call and Webcast Today at 5:00 p.m. Eastern STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the fourth quarter and fiscal year ended December 27, 2024. The Company moved up its earnings announcement and will hold a conference call and webcast today at 5:00 p.m. Eastern to discuss its financial results, oper

    2/11/25 4:01:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical to Host Fourth Quarter and Fiscal Year 2024 Earnings Conference Call and Webcast on February 19, 2025

    STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the fourth quarter and fiscal year ended December 27, 2024, on or about Wednesday, February 19 after the market close. "Our industry-leading EVO ICL technology and market-building initiatives supported our ability to achieve double-digit year-over-year ICL sales growth globally in fiscal 2024, with the exception of China," said Tom Frinzi, Chair of the Board and CEO of STAAR Surgical. "The pervasive and well-documented economic conditions and lower levels of consumer confidenc

    1/13/25 7:00:00 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical to Report Third Quarter Results on October 30, 2024

    STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the third quarter ended September 27, 2024, on Wednesday, October 30, 2024, after the market close. Event: STAAR Surgical 3Q 2024 Financial Results Webcast Date: Wednesday, October 30, 2024 Time: 4:30 p.m. ET / 1:30 p.m. PT Location: https://event.choruscall.com/mediaframe/webcast.html?webcastid=fmU0YbKB STAAR will also host an earnings webcast on Wednesday, October 30 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and op

    10/23/24 7:00:00 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Company Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by STAAR Surgical Company

    SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

    9/6/24 9:51:09 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by STAAR Surgical Company (Amendment)

    SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

    2/13/24 5:14:04 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by STAAR Surgical Company (Amendment)

    SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

    1/26/24 9:19:42 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form SC 13D/A filed by STAAR Surgical Company (Amendment)

    SC 13D/A - STAAR SURGICAL CO (0000718937) (Subject)

    1/10/24 5:23:32 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form SC 13D/A filed by STAAR Surgical Company (Amendment)

    SC 13D/A - STAAR SURGICAL CO (0000718937) (Subject)

    11/15/23 5:27:42 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form SC 13D/A filed by STAAR Surgical Company (Amendment)

    SC 13D/A - STAAR SURGICAL CO (0000718937) (Subject)

    10/10/23 8:00:27 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by STAAR Surgical Company (Amendment)

    SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

    2/9/23 11:32:50 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by STAAR Surgical Company (Amendment)

    SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

    1/19/23 11:42:16 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by STAAR Surgical Company (Amendment)

    SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

    2/14/22 5:03:05 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by STAAR Surgical Company (Amendment)

    SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

    2/10/22 8:37:54 AM ET
    $STAA
    Ophthalmic Goods
    Health Care